MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer

[1]  Hans-Gustaf Ljunggren,et al.  Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans , 2016, Cell reports.

[2]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Jean-Baptiste Veyrieras,et al.  A strategy to build and validate a prognostic biomarker model based on RT-qPCR gene expression and clinical covariates , 2015, BMC Bioinformatics.

[4]  Matthew N. McCall,et al.  On non-detects in qPCR data , 2014, Bioinform..

[5]  L. Esserman,et al.  An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk , 2013, Breast Cancer Research.

[6]  Jack Cuzick,et al.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Hasegawa,et al.  EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. , 2013, Cancer research.

[8]  J. Qian,et al.  MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11 , 2012, Oncotarget.

[9]  S. Cross,et al.  PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 , 2012, British Journal of Cancer.

[10]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[11]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[12]  T. Park,et al.  A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity , 2012, Breast Cancer Research and Treatment.

[13]  Y. Im,et al.  Clinical significance of CD151 overexpression in subtypes of invasive breast cancer , 2012, British Journal of Cancer.

[14]  R. Greil,et al.  A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.

[15]  M. Furihata,et al.  Matrix metalloproteinase-11 overexpressed in lobular carcinoma cells of the breast promotes anoikis resistance , 2011, Virchows Archiv.

[16]  Kedar S Vaidya,et al.  Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines , 2011, Clinical & Experimental Metastasis.

[17]  Charles M Perou,et al.  Systems biology and genomics of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[18]  J. Lee,et al.  Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival , 2011, BMC Cancer.

[19]  L. Esserman,et al.  A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer , 2010, Breast Cancer Research.

[20]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[21]  Johan Staaf,et al.  Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  前田 邦彦,et al.  山形県の乳癌の病理学的特性-HER2 (human epidermal growth factor receptor 2)の発現率に関する調査- , 2010 .

[23]  Carlos Caldas,et al.  PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer , 2010, Breast Cancer Research.

[24]  Barbara L. Smith,et al.  The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death , 2009, Cancer.

[25]  Taesung Park,et al.  Identification of Novel Reference Genes Using Multiplatform Expression Data and Their Validation for Quantitative Gene Expression Analysis , 2009, PloS one.

[26]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Achim Rody,et al.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.

[28]  Carlos Caldas,et al.  A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer , 2008, Breast Cancer Research.

[29]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[30]  Zhuang Liu,et al.  Drug delivery with carbon nanotubes for in vivo cancer treatment. , 2008, Cancer research.

[31]  Gabriela Alexe,et al.  High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. , 2007, Cancer research.

[32]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[33]  D. Mennerich,et al.  Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway , 2007, BMC Cancer.

[34]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2006, Breast Cancer Research and Treatment.

[35]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[37]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[38]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[39]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[42]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[43]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[45]  R. Blamey,et al.  A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.

[46]  Samir Guglani.  Death , 1890, The Lancet.

[47]  G. Tse,et al.  Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers , 2013, Breast Cancer Research and Treatment.

[48]  E. Mittendorf,et al.  High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates , 2008 .

[49]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.